Lytix Biopharma-sjefen ser lyse tider for selskapets utprøvende kreftmedisiner
Fremskritt i egne kliniske studier og for lisensieringspartner Verrica Pharmaceuticals med LTX-315. Ny legemiddelkandidat er snart klar for kliniske studier. Øystein Rekdal har gode og travle dager på jobb som direktør i det norske biotekselskapet Lytix Biopharma.

https://www.healthtalk.no/kreft/lytix-biopharma-sjefen-ser-lyse-tider-for-selskapets-utprovende-kreftmedisiner/169567?noLog=1

Fant også mye nyttig på Verrica sin side om LTX-315:
LTX-315 Mechanism of Action
Lactoferrin-derived lytic peptide LTX-315. NCI Drug Dictionary 2020.
A peptide derived from human lactoferrin, with potential lytic and immunostimulating activities.
LTX-315 may bind to the tumor cell membranes and subsequently lyse tumor cells, thereby inducing tumor cell necrosis. In turn, presentation of the tumor antigens to the immune system may induce systemic innate and adaptive immune responses mediated by anti-tumor natural killer (NK) cells, cytotoxic T lymphocytes, and natural killer T (NKT) cells. This may trigger an immune response against tumor associated antigens on tumors distant from the primary tumor.
https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lactoferrin-derived-lytic-peptide-ltx-315
LTX-315: A first-in-class oncolytic peptide that reshapes the tumor microenvironment. Lytix Biopharma 2017.
LTX-315 induces a unique type of immunogenic cell death
LTX-315 treatment leads to increased tumor infiltration of CD8+ T cells
LTX-315 demonstrates synergy with other standard of care cancer therapies
LTX-315 increases the number and diversity of T cell clones
http://www.lytixbiopharma.com/uploads/posters/SITC%202017_LTX-315_A%20first-in-class%20oncolytic%20peptide%20that%20reshapes%20the%20tumor%20microenvironment.pdf
LTX-315, CAPtivating Immunity with Necrosis. Sistigu A, Manic G, Vitale I. Cell Cycle. 2016; 15(9): 1176–1177.
LTX-315 is a helical CAP [Cationinc Antimicrobial Peptide] optimized for membrane destabilization, which has been recently shown to induce cell lysis when administered intralesionally
This [leads] to the release of immunomediators into the tumor microenvironment and unleashed an inflammatory response whereby specific cytotoxic T cells eradicated residual cancer cells.
LTX-315 epitomizes an oncolytic agent that, due to its immunogenic potential, may represent a new cancer immunotherapeutic approach for triggering tumoricidal immune responses at will
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889301/
LTX-315 Basic/Background Research
LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects. Liao HW, Garris C, Pfirschke C, et al. Cell Stress. 2019; 3(11): 348–360.

LTX-315 is an oncolytic peptide that has antitumor efficacy in mice grafted with various tumor cell lines and is currently being tested in Phase II clinical trials.
Here [the study] aimed to further evaluate LTX-315 in conditional genetic mouse models of cancer that typically resist current treatment options and to better understand the drug’s mode of action in vivo. [The study reports] LTX-315 mediates profound antitumor effects against Braf-and Pten-driven melanoma and delays the progression of Kras- and P53-driven soft tissue sarcoma in mice.
Additionally, [the study shows] in melanoma that LTX-315 triggers two sequential phases of antitumor response. The first phase of response, which begins within minutes of drug delivery into tumors, is defined by disrupted tumor vasculature and decreased tumor burden and occurs independently of lymphocytes. The second phase of response, which continues over weeks, is defined by long-term alteration of the tumor microenvironment; the changes induced by LTX-315 are most notably characterized by CD8+ T cell infiltration. [The study further shows] that these CD8+ T cells are involved in suppressing melanoma outgrowth in mice and report similar CD8+ T cell infiltration following LTX-315 treatment in melanoma and sarcoma patients.
Taken together, these findings reveal LTX-315’s multiple antitumor effects, including disrupting the tumor vasculature and promoting the conversion of poorly immunogenic tumors into ones that display antitumor T cell immunity.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859426/
Cell cycle progression data on human skin cancer cells with anticancer synthetic peptide LTX-315 treatment. Santa-Gonzalez GA, Patino-Gonzalez E, Manrique-Moreno M. Data in Brief. 2020; 20: 105443.
Skin cancer, including melanoma and non-melanoma (NMSC), represents the most common type of malignancy in the white population. The incidence rate of melanoma is increasing worldwide, while the associated mortality remains stable. On the other hand, the incidence of NMSC varies widely.
Camilio and collaborators recently described the anticancer properties of LTX-315, a novel synthetic anticancer peptide, commercialized as Oncopore™. Despite various studies demonstrating the efficiency of LTX-315 therapy in inducing cancer cell death, the effects on cell cycle progression of this antitumoral peptide are poorly understood.
In this research, [the study presents] data about the effect of LTX-315 on the cell cycle of two skin cancer cell lines: epidermoid carcinoma cells (A431) and melanoma cells (A375); as well as on an immortalized normal keratinocyte cell line, HaCaT. Additionally, its cytotoxicity on the cells was determined by measuring the uptake of propidium iodide, in order to establish its relationship with cell cycle progression. The analysed data obtained by flow cytometry show different cell cycle distributions in non-tumoral and skin cancer-derived cell lines in response to LTX-315 treatment. Non-tumoral cells showed a sub-G1 peak, while for tumoral cells there was a shift in the G1peak without producing an obvious distant and distinct sub-G1 peak. This data is in accordance with a major decrease in cell viability in non-cancer cells.
https://www.sciencedirect.com/science/article/pii/S2352340920303371
LTX-315 Clinical Data
LTX-315 Clinical Trials. Clinicaltrials.gov 2020.
List of Ongoing and Completed Clinical Trials Registered with ClinicalTrials.gov.
https://clinicaltrials.gov/ct2/results?cond=&term=ltx315&cntry=&state=&city=&dist=
https://verrica.com/key_publications/about-ltx-315/

StockWizard, legger du inn ticker?
Synd at Lytix har blitt uforskyldt rammet av ULTI fiaskoen, og synd for både aksjonærer og ansatte i selskapet, samt kreftpasienter at ULTI sin teknologi ikke ser ut til å fungere særlig optimalt.
Lytix har som du lister opp i starttråden en helt annen innfallsmetode mhp. kreftbehandling, hvor stimulering av kroppens eget forsvarsverk, T- cellene er det essensielle. Lytix sin teknologi skal også kunne behandle nye muterte kreftceller, noe som er særdeles viktig for å kunne ta knekken på kreftsvulsten.

Abstract: 07.12.2023

LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma

LTX-315 is an oncolytic peptide that elicits both local and systemic immune responses upon intratumoral injection. In the present pilot trial, we treated patients with metastatic soft tissue sarcoma with the combination of LTX-315 and adoptive T-cell therapy using in vitro expanded tumor-infiltrating lymphocytes. Six heavily pretreated patients were included in the trial and treated with LTX-315 of which four patients proceeded to adoptive T-cell therapy. Overall, the treatment was considered safe with only expected and manageable toxicity. The best overall clinical response was stable disease for 208 days, and in this patient, we detected tumor-reactive T cells in the blood that lasted until disease progression. In three patients T-cell reactivity against in silico predicted neoantigens was demonstrated. Additionally, de novo T-cell clones were generated and expanded in the blood following LTX-315 injections. In conclusion, this pilot study provides proof that it is feasible to combine LTX-315 and adoptive T-cell therapy, and that this treatment can induce systemic immune responses that resulted in stabilization of the disease in sarcoma patients with otherwise progressive disease. Further optimization of the treatment protocol is warranted to increase clinical activity. ClinicalTrials.gov Identifier: NCT03725605


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10732595/

Abstract desember-2022

Interventional Oncolytic Immunotherapy with LTX-315 for Residual Tumor after Incomplete Radiofrequency Ablation of Liver Cancer

Radiofrequency ablation (RFA) is a favorite treatment approach for patients with liver cancer, one of the most common malignancies worldwide. However, incomplete RFA often occurs in irregular and medium-to-larger (>3 cm) hepatic tumors. The aim of this study was to validate the feasibility of interventional oncolytic immunotherapy with LTX-315 for residual tumors after incomplete RFA of liver cancers. LTX-315, injected into tumor margins through the electrode prongs during the ablation procedure, can directly kill tumor cells and activate an anti-tumor immune response. This treatment strategy facilitated the creation of a clear ablated tumor margin. The evidence of this study may open up new avenues to prevent residual tumors after RFA of irregular and medium-to-large liver cancers.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777024/

Også LTX nevnt som "LTX-315, one of the most promising and extensively studied oncolytic peptides"

Oncolytic peptides are highly effective on remodeling the tumor microenvironment and potentiating the anticancer immunity through multiple mechanisms, particularly by inducing immunogenic cell death. Intriguingly, a recent study demonstrates that LTX-315, one of the most promising and extensively studied oncolytic peptides, inhibits PD-L1 expression via ATP11B, thus enhancing the effectiveness of cancer immunotherapy by targeting the PD-1/PD-L1 axis. Therefore, this commentary discusses the broad effects and perspectives of oncolytic peptides on anticancer immunity, further highlighting the potential issues and directions of oncolytic peptides in cancer immunotherapy.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295653/

Mange artikler om LTX-315 i behandling av lever-kreft (HCC):

Intratumoral RFA-associated RFH could enhance the efficacy of immunochemotherapy of LTX-315 with liposomal doxorubicin for HCC, which may provide a new strategy to increase the curative efficacy of thermal ablation for medium-to-large HCC.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717415/

Ser nå frem til bekreftet års rapport den 21 mars. Håper det blir en etterlengtet opptur etter et lengre unødvendig fall som ikke Lytix fortjente.

Jeg forventer tre større meldinger og en mindre viktig melding (for min del) innen H1:
- Oppstart av Melanom Neoadjuvant studien (som kan komme når som helst) kan gi litt boost og vekke oppmerksomhet
- Melding om finansieringsplan for 90 millioner (etter estimering fra Redeye)
- Melding om ny partneravtale (se på Q-rapport), som faktisk kan være "den finansieringsplanen"
- Verrica read out for BCC innen H1 (31.06.24) som kan gi ATH ved overaskende gode resultater (som ved rapport av del1 fase2 august-23)

Ny artikkel publisert i dag 13.03.24: kortsagt viser/bekrefter enda mere potensiale av LTX-315 i melanom behandling :)

LTX-315 triggers anticancer immunity by inducing MyD88-dependent maturation of dendritic cells

LTX-315 is a synthetic cationic oncolytic peptide with potent anticancer activity but limited toxicity for non-malignant cells. LTX-315 induces both immunogenic tumor cell death and generation of tumor-specific immune responses in multiple experimental tumor models. Given the central role of dendritic cell (DC) maturation in the induction of antigen-specific immunity, we investigated the effect of LTX-315 treatment on the maturation of tumor-infiltrating DCs (TiDCs) and the generation of anti-melanoma immunity. We found that LTX-315 treatment induces the maturation of DCs, both indirectly through the release of cancer cell-derived damage-associated molecular patterns (DAMPs)/alarmins and nucleic acids (DNA and RNA) capable of triggering distinct Toll-like receptor (TLR) signaling, and, directly by activating TLR7. The latter results in the ignition of multiple intracellular signaling pathways that promotes DC maturation, including NF-κB, mitogen activated protein kinases (MAPKs), and inflammasome signaling, as well as increased type 1 interferon production. Critically, the effects of LTX-315 on DCs the consequent promotion of anti-melanoma immunity depend on the cytosolic signal transducer myeloid differentiation response gene 88 (MyD88). These results cast light on the mechanisms by which LTX-315 induces DC maturation and hence elicits anticancer immunity, with important implications for the use of LTX-315 as an anticancer
immunotherapeutic.

https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1332922/full?utm_source=F-NTF&utm_medium=EMLX&utm_campaign=PRD_FEOPS_20170000_ARTICLE

Jeg søker ofte målrettet å finne en artikkel som "mislykket forsøk med LTX-315", men bare finner nye og sterkere positive påfyll som forsterker min optimisme om LYTIX! Dumt ;D

Denne ble publisert i går :D

Three Rounds of Stability-Guided Optimization and Systematical Evaluation of Oncolytic Peptide LTX-315
Abstract
Oncolytic peptides represent promising novel candidates for anticancer treatments. In our efforts to develop oncolytic peptides possessing both high protease stability and durable anticancer efficiency, three rounds of optimization were conducted on the first-in-class oncolytic peptide LTX-315. The robust synthetic method, in vitro and in vivo anticancer activity, and anticancer mechanism were investigated. The D-type peptides represented by FXY-12 possessed significantly improved proteolytic stability and sustained anticancer efficiency. Strikingly, the novel hybrid peptide FXY-30, containing one FXY-12 and two camptothecin moieties, exhibited the most potent in vitro and in vivo anticancer activities. The mechanism explorations indicated that FXY-30 exhibited rapid membranolytic effects and induced severe DNA double-strand breaks to trigger cell apoptosis. Collectively, this study not only established robust strategies to improve the stability and anticancer potential of oncolytic peptides but also provided valuable references for the future development of D-type peptides-based hybrid anticancer chemotherapeutics.

https://pubmed.ncbi.nlm.nih.gov/38278140/

Også denne!
Overrasker meg at selskapet/LYTIX ikke melder slike forsøk og artikler (publisert des.-23). Sender nå en email til selskapet angående artikelen å spør om de vet om forsøket?! Kombinasjon av LTX-315 og adoptiv T-celle therapy pasienter (ikke lab. eller forsøksdyr) med metastatisk sarcom!

LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma

ABSTRACT
LTX-315 is an oncolytic peptide that elicits both local and systemic immune responses upon intratumoral injection. In the present pilot trial, we treated patients with metastatic soft tissue sarcoma with the combination of LTX-315 and adoptive T-cell therapy using in vitro expanded tumor-infiltrating lymphocytes. Six heavily pretreated patients were included in the trial and treated with LTX-315 of which four patients proceeded to adoptive T-cell therapy. Overall, the treatment was considered safe with only expected and manageable toxicity. The best overall clinical response was stable disease for 208 days, and in this patient, we detected tumor-reactive T cells in the blood that lasted until disease progression. In three patients T-cell reactivity against in silico predicted neoantigens was demonstrated. Additionally, de novo T-cell clones were generated and expanded in the blood following LTX-315 injections. In conclusion, this pilot study provides proof that it is feasible to combine LTX-315 and adoptive T-cell therapy, and that this treatment can induce systemic immune responses that resulted in stabilization of the disease in sarcoma patients with otherwise progressive disease. Further optimization of the treatment protocol is warranted to increase clinical activity. ClinicalTrials.gov Identifier: NCT03725605

https://www.tandfonline.com/doi/full/10.1080/2162402X.2023.2290900

Ser ut som om at selskapet ikke vil ha kursen opp før den 21 d.mnd. Men her kan komme en rekyl når som helst.

Sendte denne mailen til selskapet!
Også oppfordrer folk å være proaktiv å kommunisere med selskapet og formidle sine meninger :)

"Hei,
Som en kreftlege og investor er jeg begeistret over LYTIX sin effekt og fremtid med stor potensial for å etablere seg for behandling av solide tumorer.
Jeg syns at LYTIX aksjekurs har fått ufortjent juling på Oslo Børs av forskjellige grunner, hvor jeg tidligere har kommunisert med selskapet (Gjest Breistein) og forespeilet mine synspunkter.

En ting kan jeg klage over at selskapet er litt treg for å kommunisere med markedet.
For eksempel fant jeg to fersk artikler fra mars-24 hvor den ene er om LYTIX potensiale på Malign. melanom som faktisk hadde fortjent en børsmelding.

https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1332922/full?utm_source=F-NTF&utm_medium=EMLX&utm_campaign=PRD_FEOPS_20170000_ARTICLE


Også denne artiklen (fra desember-23) om behandling/forsøk på pasienter med "kombinasjonsbehandling av LTX-315 og adoptiv T-celle behandling" med overbevisende resultater! Har selskapet noe kjennskap til forsøket?

https://www.tandfonline.com/doi/full/10.1080/2162402X.2023.2290900

Mvh,
..............

Lovende ordrebildet nå

Kjekt at noen (du) deler info her som holder liv i forumet. Takkar.

Hei,

Håper at denne informasjonen stemmer angående at fagfolk er på vei inn og at det ikke er for å hause. Har selv hatt Malignt Melanom(dog fikk jeg tatt den tidlig) så ikke mer behandling enn en operasjon rundt føflekken. Håper Lytix med partnere klarer å løse denne kreftgåten og andre :-)!
Har bare en liten lyttepost her, men kan jo bli verdt mye det om de lykkes!

Nå skjønner jeg hvorfor du har så god kunnskap om Lytix og har tro på selskapet StockWizard. Når en kreftlege går tungt inn i Lytix er det for meg et solid kjøpssignal.
Har selv kjøpt Lytix hele veien fra kr. 14,- i 2021 og sitter på en solid aksjepost i selskapet. Har virkelig trua på dette selskapet.

Velger å slette mitt innlegg for "vennegjeng/fagfolk" for at denne tråden ikke blir en hausetråd :)
Foretrekker å holde tråden ren faktabasert :)

Godt tiltag. Mange er ikke klar over, at aktien til tider fremstår nærmest illikvid, dvs nærest umuligt at handle/sælge uden kurset falder drastisk. Bedre at få investorer ind, der har de lange briller på. Utålmodighed er denne akties værste fjende.

:-)

Tilbakemelding fra LYTIX!
Slik dere ser, bli de glad om å høre aksjonærens synspunkter og engasjement :)
Jeg sendte også et ekstra spørsmål :)

"Hei ...,
Takk for ditt engasjement i Lytix.
Vedørende de to artiklene du sikter til å så har vi delt dette med markedet. Nyheten om artikkelen i Frontiers In Immunology ble tatt med i Q4 presentasjonen og artikkelen fra desember sendte vi en egen børsmelding på da den ble tilgjengelig. https://newsweb.oslobors.no/message/606165

Samtidig, er det viktig at vi tar til oss tilbakemeldinger fra markedet og vi vil se på hvilke grep vi kan gjøre for å få artiklene bedre kjent.
Mvh
Gjest"

Mitt spørsmål:

Hei Gjest,
Takk for rask tilbakemelding :)
Hva med den andre artikkelen hvor de har behandlet 6 metastatisk sarcom pasienter og stabilisert sykdomen? Er dette kjent for selskapet?
Mvh,
......"

Takk for flott initiativ! Har selv funnet flere forskningsrapporter datert i 2024 der LTX-315 var med - Veldig gode resultater i alle og enig i at Lytix kunne vært mye flinkere med å kommunisere utad! Fikk opp mange rapporter og hvis jeg ikke husker feil var det en rapport der de også hadde svært gode resultater med at transplanasjonspasienter fikk mye mindre problemer med avstøting av det nye organet - Ganske utrolig...
Håper de responderer på klagen din og blir mer aktive mot utenverdenen!
Forhåpentligvis får vi enda bedre tilbakemeldinger på Q1 :-)

Hva skjer den 21 d. mnd. ?

21.03.2024 - Annual Report 18.04.2024 - Annual General Meeting
Står på DNBs Lytix side Financial calender) .

Flott at de svarte så fort og skjønner at info fra de bør bli mer synlig. Ser for meg en fin opptur i nær fremtid.

Snart ikke mulig å få kjøpt under 7 kr. antagelig pga. møte den 21.

Som tidligere har jeg skrevet, venter jeg spent på to viktige meldinger ila og en mindre viktig (for min del) ila H1 med STORE konsekvenser på kurs:

- melding for oppstart av neoadjuvant behandling (FPD: første pasient dosert) i malignant melanom: jeg forventer ikke kursrally, men den kan gi litt oppmerksomhet og booste kurset
- melding om finansieringsplan: alt av emisjon (mindre sannsynlig etter min mening), partneravtale (nevnt som en av alternativer på Q-rapport), konvertibel lån fra deres amerikansk Finance partner (sannsynlig) eller milestone utbetaling fra Verrica.
- Studie read out fra Verrica i H1 (senest 31.06.24).

Sist nevnte to meldinger kan gi ATH kurs, spesielt etter mediadekkning som i fjor (på TV2). Der kommer skuffede folk fra andre biotek OB å kaste seg over LYTIX som kan gi tidenes kursrally :D

Litt gammel artikkel (januar 2024), men interessant som bekrefter/gjentar alle prinsipper av LTX-315 som er kjent fra tidligere LYTIX presentasjoner:

Allogeneic “Zombie Cell” as Off-The-Shelf Vaccine for Postsurgical Cancer Immunotherapy

Allogeneic tumor cell vaccines provide off-the-shelf convenience but lack patient specificity due to heterogeneity in tumor antigens. Here, allogeneic tumor cell corpses are converted into “zombie cells” capable of assimilating heterogeneous tumor by seizing cancer cells and spreading adjuvant infection. This causes pseudo-oncolysis of tumors, transforming them into immunogenic targets for enhanced phagocytosis. It is shown that in postoperative tumor models, localized delivery of premade “zombie cells” through stepwise gelation in resection cavity consolidates tumor surgery. Compared to analogous vaccines lacking “seizing” or “assimilating” capability, “zombie cell” platform effectively mobilizes T cell response against residual tumors, and establishes immunological memory against tumor re-challenge, showing less susceptibility to immune evasion. Despite using allogeneic sources, “zombie cell” platform functions as generalizable framework to produce long-term antitumor immunity in different tumor models, showing comparable effect to autologous vaccine. Together, with the potential of off-the-shelf availability and personalized relevance to heterogenous tumor antigens, this study suggests an alternative strategy for timely therapy after tumor surgery.
In the present study, we designed a “zombie cell” vaccine to stimulate immune responses specific to residual tumors after surgery. “Zombie cells” were referred to allogeneic cell corpses that were pretreated with clinical-grade oncolytic peptide of LTX-315, succumbing to oncolysis, emitting adjuvanting DAMPs, further armed with artificial ligand, and fabricated ex vivo.

https://onlinelibrary.wiley.com/doi/full/10.1002/advs.202307030

Denne artikkelen nevner LTX-315 som en "perfekt model" for fremtidens oncolytiske peptider! Man nesten får orgasme å lese artikler om LTX-315 :D

LTX-315 is a clinical-stage, anticancer peptide therapeutic that disrupts cancer cell membranes. Existing mechanistic knowledge about LTX-315 has been obtained from cell-based biological assays, and there is an outstanding need to directly characterize the corresponding membrane-peptide interactions from a biophysical perspective. Herein, we investigated the membrane-disruptive properties of the LTX-315 peptide using three cell-membrane-mimicking membrane platforms on solid supports, namely the supported lipid bilayer, intact vesicle adlayer, and tethered lipid bilayer, in combination with quartz crystal microbalance-dissipation (QCM-D) and electrochemical impedance spectroscopy (EIS) measurements. The results showed that the cationic LTX-315 peptide selectively disrupted negatively charged phospholipid membranes to a greater extent than zwitterionic or positively charged phospholipid membranes, whereby electrostatic interactions were the main factor to influence peptide attachment and membrane curvature was a secondary factor. Of note, the EIS measurements showed that the LTX-315 peptide extensively and irreversibly permeabilized negatively charged, tethered lipid bilayers that contained high phosphatidylserine lipid levels representative of the outer leaflet of cancer cell membranes, while circular dichroism (CD) spectroscopy experiments indicated that the LTX-315 peptide was structureless and the corresponding membrane-disruptive interactions did not involve peptide conformational changes. Dynamic light scattering (DLS) measurements further verified that the LTX-315 peptide selectively caused irreversible disruption of negatively charged lipid vesicles. Together, our findings demonstrate that the LTX-315 peptide preferentially disrupts negatively charged phospholipid membranes in an irreversible manner, which reinforces its potential as an emerging cancer immunotherapy and offers a biophysical framework to guide future peptide engineering efforts.

https://www.mdpi.com/1422-0067/23/18/10558

Oppfordrer folk her å sende mail til "Radium Podcast" og be om å invitere LYTIX til en poscast! Jeg har sendt en forspørsel :)
Vi må gjøre LYTIX mere synlig på Oslo Børs :)

Forespørsel sendt til "Radium Podcast"

Bra! :)
Jeg har også sendt en mail til Gjest Breistein på LYTIX og bedt om å "forberede seg" til podcasten :)

"Hei Gjest,
Takk for en flytende kommunikasjon og raske tilbakemeldinger :)
Som en tiltak for synliggjøring av LYTIX for biotek-miljøet i Norge er det smart å ha et intervju på "Radium Podcast" hvor alle biotekselskaper på Oslo Børs jevnlig deltar og gir oppdateringer.
Mvh,
........
........"

Det ser ut at noen kortsiktige er skuffet over børsmeldingen og kaster kortene! Salgpost på 46000 aksjer på 6,85 :D

"Financial calendar for Lytix Biopharma AS
FINANCIAL YEAR 2024
30.04.2024 - Annual Report

FINANCIAL YEAR 2024

29.08.2024 - Half-yearly Report
14.05.2024 - Annual General Meeting

30.05.2024 - Quarterly Report - Q1
14.11.2024 - Quarterly Report - Q3

The date of the annual report is changed to April 30, 2024 , the date of the annual general meeting is changed to May 14, 2024, and the date of the Q1 report is changed to May 30, 2024.

This information is published pursuant to the requirements set out in the Continuing obligations."

https://newsweb.oslobors.no/message/614147

Disse dataene er svært overbevisende og forklarer videre hvordan LTX-315 er i stand til å generere brede T-celleresponser hos de fleste kreftpasienter. Funnene representerer et viktig skritt mot å realisere det fulle translasjonspotensialet til LTX-315 og ytterligere styrke posisjonen til LTX-315 som et potent antikreft immunoterapeutisk middel som er ideelt å kombinere med andre typer immunterapier, sier Øystein Rekdal, administrerende direktør i Lytix Biopharma. .

«LTX-315 er designet for å drepe kreftceller på en måte som effektivt eksponerer deres tumorantigener. Dataene fra dette papiret dokumenterer at LTX-315 har en ekstra antikrefteffekt ved å aktivere APC-er (dendritiske celler) som er spesialiserte til å plukke opp tumorantigener og presentere dem for T-cellene. Gjennom denne doble virkemåten har LTX-315 to mekanismer som begge er kritiske for å øke sterke T-celleresponser.»

Det er ikke negativt

Det ser ut at LYTIX har begynt å kjenne viktigheten av kontinuerlig kommunikasjon med investormarked etter å fått mine mail (påminnelser/klager ;)!
Viser til mitt innlegg fra 15.03. hvor jeg hadde klaget over at artikkelen var publisert uten oppmerksomhet fra LYTIX :D
Fortsett folkens! Dette viser hvor viktig er å kommunisere med selskapet. LYTIX er flink å høre på deres meninger og forslag :)
Det er en av mine flere grunner å like selskapet :)

Forløpig ser det ut til at enkelte aksjonerer er villig til å selge den nedover.